UCB Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Jean-Christophe Tellier
İcra Kurulu Başkanı
€12.4m
Toplam tazminat
| CEO maaş yüzdesi | 11.26% |
| CEO görev süresi | 11.3yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 5.8yrs |
| Yönetim Kurulu ortalama görev süresi | 8.6yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Anlatı Güncellemesi • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Anlatı Güncellemesi • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Anlatı Güncellemesi • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Anlatı Güncellemesi • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Anlatı Güncellemesi • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Anlatı Güncellemesi • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Anlatı Güncellemesi • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Anlatı Güncellemesi • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Anlatı Güncellemesi • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Anlatı Güncellemesi • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Anlatı Güncellemesi • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Anlatı Güncellemesi • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Analiz Makalesi • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Anlatı Güncellemesi • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Anlatı Güncellemesi • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Analiz Makalesi • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Anlatı Güncellemesi • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Anlatı Güncellemesi • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Anlatı Güncellemesi • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Analiz Makalesi • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Yeni Anlatı • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 31 2025 | €12m | €1m | €2b |
| Sep 30 2025 | n/a | n/a | €1b |
| Jun 30 2025 | n/a | n/a | €1b |
| Mar 31 2025 | n/a | n/a | €1b |
| Dec 31 2024 | €7m | €1m | €1b |
| Sep 30 2024 | n/a | n/a | €653m |
| Jun 30 2024 | n/a | n/a | €240m |
| Mar 31 2024 | n/a | n/a | €292m |
| Dec 31 2023 | €7m | €1m | €343m |
| Jun 30 2023 | n/a | n/a | €332m |
| Mar 31 2023 | n/a | n/a | €376m |
| Dec 31 2022 | €6m | €1m | €420m |
| Jun 30 2022 | n/a | n/a | €887m |
| Mar 31 2022 | n/a | n/a | €971m |
| Dec 31 2021 | €6m | €1m | €1b |
| Sep 30 2021 | n/a | n/a | €996m |
| Jun 30 2021 | n/a | n/a | €936m |
| Mar 31 2021 | n/a | n/a | €834m |
| Dec 31 2020 | €7m | €1m | €732m |
| Jun 30 2020 | n/a | n/a | €743m |
| Mar 31 2020 | n/a | n/a | €767m |
| Dec 31 2019 | €87k | n/a | €790m |
Tazminat ve Piyasa: Jean-Christophe 'nin toplam tazminatı ($USD 14.42M ), Belgian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.86M ).
Tazminat ve Kazançlar: Jean-Christophe 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Jean-Christophe Tellier (66 yo)
11.3yrs
Görev süresi
€12,434,367
Tazminat
Dr. Jean-Christophe Tellier is Chief Executive Officer of UCB Ventures S.A. Dr. Jean-Christophe Tellier is CEO & Executive Director of UCB SA from July 01, 2020. Dr. Tellier served as Executive Vice Presid...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 11.3yrs | €12.43m | Veri yok | |
| Executive VP & CFO | 5.8yrs | Veri yok | Veri yok | |
| Executive VP & Chief Scientific Officer | 2yrs | Veri yok | Veri yok | |
| Executive VP & General Counsel | 3.1yrs | Veri yok | Veri yok | |
| Executive VP & Chief Human Resources Officer | 6.3yrs | Veri yok | Veri yok | |
| Executive Vice President of Patient Evidence | 11.3yrs | Veri yok | Veri yok | |
| Executive Vice President of Patient Supply | 2.3yrs | Veri yok | Veri yok | |
| Executive VP of Patient Impact & Chief Commercial Officer | 2.1yrs | Veri yok | Veri yok | |
| Chief Accounting Officer & Head of Group Finance | 13.2yrs | Veri yok | Veri yok | |
| Head of Global Corporate Communication | no data | Veri yok | Veri yok | |
| Head of Sustainability | no data | Veri yok | Veri yok | |
| VP & Head of Neuroscience TA New Medicines | no data | Veri yok | Veri yok |
5.8yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş
Deneyimli Yönetim: UCB 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 12.1yrs | €12.43m | Veri yok | |
| Honorary Chairman | no data | €70.00k | Veri yok | |
| Honorary Chairman | 21.3yrs | €15.50k | Veri yok | |
| Honorary Deputy Chairman | no data | €28.50k | Veri yok | |
| Honorary Chairman | no data | €30.00k | Veri yok | |
| Honorary Chairman | 5.1yrs | €87.50k | Veri yok | |
| Honorary Chairman | no data | €49.00k | Veri yok | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Independent Chair of the Board | 5.1yrs | €438.33k | Veri yok | |
| Vice-Chair of the Board | 14.1yrs | €192.33k | Veri yok | |
| Independent Director | 2.3yrs | €197.33k | Veri yok | |
| Director | 12.1yrs | €157.83k | Veri yok |
8.6yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: UCB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.6 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 18:43 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
UCB SA 40 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |